TrialScientific reports2019

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.

A Borrero-Palacios et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.